Biotech SF: Knickerbocker Properties

Showing posts with label Knickerbocker Properties. Show all posts

Friday, January 13, 2012

Medivation bounces back with new drug, new lease

The second time may be a charm for Medivation in downtown San Francisco.
Nearly two years ago the San Francisco biotech terminated a 63,817-square-foot lease at 345 Spear St. following a disappointing Phase III trial for Dimebon, the Alzheimer’s drug the company was developing with Pfizer. Now Medivation has a new promising drug — this one a late-stage cancer drug — and a big new lease to go along with it.

Subscribe to: Posts (Atom)

Some of my favorite stories.

• "The fight of his life" (2007)

Last year Mike Homer helped raise the money for 2,000 medical research computers. Now researchers are using that equipment in an attempt to save his life.

• "For reporter, CJD is more than a story" (2007)

Seven years ago -- nearly to the day -- my mother died of Creutzfeld-Jakob Disease.

• "A son's YouTube plea for Avastin" (2010)

Josh Turnage is your typical teenager, trying to discover what he wants to do in college and with his life. But a 7-minute, 41-second YouTube video he produced about his mother's fight with breast cancer may thrust him into a debate between drug makers and the agency that regulates them.

• "New device could knock out old dialysis technology" (2011)

Shuvo Roy has all the makings for the world's first implantable artificial kidney, thanks to nanotechnology and a web of nationwide collaborations.

All he needs now is $20 million.